Lexeo Therapeutics, Inc. financial data

Symbol
LXEO on Nasdaq
Location
345 Park Avenue South, Floor 6, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 487 % -37.5%
Debt-to-equity 27.7 % +40.9%
Return On Equity -90.5 % -56.9%
Return On Assets -70.8 % -47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 73M shares +121%
Common Stock, Shares, Outstanding 54.9M shares +66.2%
Entity Public Float 528M USD
Common Stock, Value, Issued 5K USD +66.7%
Weighted Average Number of Shares Outstanding, Basic 61M shares +84.4%
Weighted Average Number of Shares Outstanding, Diluted 61M shares +84.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 66M USD +3.16%
General and Administrative Expense 47.6M USD +61.7%
Operating Income (Loss) -114M USD -21.6%
Nonoperating Income (Expense) 8.56M USD +26.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -105M USD -21.2%
Net Income (Loss) Attributable to Parent -105M USD -21.2%
Earnings Per Share, Basic -2 USD/shares -115%
Earnings Per Share, Diluted -2 USD/shares -115%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41M USD -73.9%
Cash, Cash Equivalents, and Short-term Investments 107M USD
Other Assets, Current 3K USD -99.2%
Assets, Current 128M USD -19.9%
Property, Plant and Equipment, Net 1.23M USD +4.24%
Operating Lease, Right-of-Use Asset 6.96M USD -17.5%
Assets 144M USD -17.3%
Accounts Payable, Current 4.66M USD -44.8%
Liabilities, Current 17.3M USD -35.6%
Operating Lease, Liability, Noncurrent 5.29M USD -22.1%
Liabilities 23M USD -33.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 89K USD
Retained Earnings (Accumulated Deficit) -359M USD -41.3%
Stockholders' Equity Attributable to Parent 121M USD -13.3%
Liabilities and Equity 144M USD -17.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.7M USD -46.1%
Net Cash Provided by (Used in) Financing Activities 88.7M USD
Net Cash Provided by (Used in) Investing Activities 15.6M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 54.9M shares +66.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.11M USD -108%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 44.2M USD -72.4%
Deferred Tax Assets, Valuation Allowance 95.4M USD +54%
Deferred Tax Assets, Gross 98.4M USD +50.6%
Operating Lease, Liability 7.44M USD -16.5%
Payments to Acquire Property, Plant, and Equipment 185K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -105M USD +31.6%
Lessee, Operating Lease, Liability, to be Paid 8.7M USD -19.8%
Property, Plant and Equipment, Gross 1.9M USD +6.03%
Operating Lease, Liability, Current 2.15M USD +1.85%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.26M USD +2.49%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.21M USD +2.51%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.27M USD -34.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.32M USD +2.52%
Deferred Tax Assets, Operating Loss Carryforwards 33.3M USD +52%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.37M USD -40.8%
Operating Lease, Payments 2.14M USD +2%
Deferred Tax Assets, Net of Valuation Allowance 2.98M USD -11.5%
Share-based Payment Arrangement, Expense 12.9M USD +32.3%
Interest Expense 174K USD -34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%